Courtesy of Benzinga.
Jazz Pharmaceuticals (NASDAQ: JAZZ) released its Q4 earnings results after the closing bell on Monday. The company reported EPS of $1.17, which compared to analysts’ consensus estimates of $1.09.
Revenues for the quarter were $83.5 million versus consensus estimates of $80.84 million.
In Monday’s after hours trading session, JAZZ shares are trading up a little better than 2% to $51.70.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
